AGP Executive Report

Cancer Screening: India’s Rajiv Gandhi Centre for Biotechnology won a ₹7 crore grant to develop an automated blood test for early cervical cancer detection. The device is still in development and will need validation. Cancer Treatment: The FDA granted accelerated approval to Jemperli for adults with stage II or III MSI-H/dMMR locally advanced rectal cancer, offering a new option for a biomarker-defined group. Heart and Kidney Health: A review found intensive blood-pressure lowering cut major cardiovascular events by 15% per 10 mm Hg reduction, with similar benefits in people with and without chronic kidney disease. It did not prevent kidney failure and increased the risk of sustained kidney-function decline. Flu Prevention: Spokane County reported its first flu-related death of the season; health officials urge vaccination, recommended for everyone aged 6 months and older. Separately, an EU advisory panel backed extending AstraZeneca’s H5N1 vaccine eligibility to adults. Brain Health: In a small study, 20 minutes of aerobic exercise helped preserve memory after 30 hours without sleep, with results comparable to a 90-minute nap.

Diabetes Care: The FDA cleared Sequel’s Twiist automated insulin-delivery system for adults with insulin-treated Type 2 diabetes. In a 13-week study, users spent more time in the target blood-sugar range. Drug Development: An FDA pilot aims to cut delays in first-in-human trials by letting qualified research institutions coordinate key steps; the first cohort will be small. Rare Disease: Bitopertin met all primary and secondary endpoints in a Phase 3 trial for erythropoietic protoporphyria, a rare condition that causes painful reactions to light. The drug remains investigational. Cancer Access: India will cap trade margins on 137 cancer medicines starting Nov. 9, a move expected to lower costs for some patients. Biotech Investment: Germany’s sector is drawing major pharma partnerships and acquisitions, including Gilead’s reported €4.48 billion purchase of Tubulis.

Cancer Drug Access: India has capped trade margins at 30% for 137 cancer medicines, with some prices expected to fall by up to 70% from Nov. 9; actual reductions will vary. Healthcare Capacity: Tata Trusts plans 40–50 not-for-profit hospitals and a five-year push to expand primary care and train frontline workers, though locations and timing are not yet set. Drug Development: Novartis has ended its phase 2 Fabhalta trial for lupus nephritis, citing strategic considerations, while upcoming patent expiries are driving biosimilar companies to expand their pipelines. Emergency Care: Alberta is launching physician-led triage to begin assessments and tests earlier for patients waiting in emergency departments. Respiratory Health: CHEST 2026 analyses linked sputum purulence with bronchiectasis activity and found mepolizumab reduced steroid exposure in eosinophilic COPD; separate observational research associated chronic proton-pump inhibitor use with more asthma exacerbations. Fertility Advice: An infertility specialist recommends addressing modifiable habits, including smoking and diet, before treating IVF as the first step.

HIV Care: Updated HHS guidelines recommend dolutegravir/lamivudine for some adults regardless of viral load, while a newly approved combination remains under review. Youth Mental Health: A new report says one in six teens has anxiety, with many also experiencing suicidal thoughts. Menopause: A Finnish study of 2,632 women linked reaching late perimenopause or menopause by age 46 with more anxiety and depressive symptoms; it does not establish cause and effect. Infection and Gut Health: Among hospitalized blood-cancer patients, higher sugar intake around antibiotic treatment was associated with greater loss of beneficial gut bacteria and growth of potentially harmful microbes. Outbreak Watch: The Ebola outbreak in the Democratic Republic of Congo has topped 9,235 confirmed cases, while Kenya has reported a third case. Drug Access: India will cap trade margins on 137 cancer drugs at 30%, with revised prices due from Nov. 9. Healthcare Staffing: UPMC Enterprises invested in VeloSource to expand an AI-enabled clinician staffing platform as health systems face persistent workforce shortages.

Cancer Drug Costs: India has capped trade margins at 30% for 137 cancer medicines, with revised prices due Nov. 9 and some retail prices expected to fall by up to 70%. GLP-1 Research: A review of clinical trials found semaglutide and tirzepatide were linked to reduced sleep-apnea severity and cardiovascular risk; weight loss explained only part of some benefits. Ebola Watch: The DRC outbreak has passed 9,200 confirmed cases, according to the CDC, which reports no U.S. cases linked to the outbreak and says risk to the American public remains low. New Epilepsy Treatments: Morocco’s Sothema won approval for three cannabis-based epilepsy medicines, though launch dates and prices have not been announced. Child Health: Researchers detected an average of 31 pesticide-related compounds in urine samples from each of 187 children, raising questions about exposure to chemical mixtures. Antibiotic Stewardship: A new review says AI may help flag patients for antibiotic review, but incomplete records and prescribing patterns limit its reliability.

Cancer Drug Costs: India’s NPPA capped trade margins at 30% on 137 commonly used cancer drugs, with revised prices taking effect Nov. 9; Keytruda is excluded. Health Workforce: Nepal added 418 government medical-education seats, including 110 for medical degrees and 210 for nursing. Industry Safety: A fire broke out in the herbal division of a medicine factory in Bangladesh; no injuries were reported initially. Infectious Disease: US measles cases reached 4,410, including five confirmed deaths in Pennsylvania, while WHO urged vigilance after a second Ebola case in Kenya. Treatment Advances: EU regulators backed Foundayo, an oral medicine for obesity and type 2 diabetes. In a small trial, a long-acting HIV drug combination kept all 46 participants virally suppressed. Care Access: New findings suggest glucose monitors may benefit people with type 2 diabetes who do not use insulin.

Pediatric Heart Care: Providence Heart Institute has opened a children’s cardiac catheterization lab, offering minimally invasive heart procedures in a space designed for young patients. Menopause Care: ACOG issued its most comprehensive guidance yet, covering hormone, nonhormone and other options for hot flashes, sleep problems and mood symptoms. Drug Updates: The FDA cleared Enspryng for thyroid eye disease and expanded Anktiva’s use for a type of bladder cancer; Europe’s medicines committee also backed the oral weight-loss drug Foundayo. HIV Treatment: A 46-patient case series found long-acting lenacapavir plus cabotegravir maintained viral suppression, including among people facing housing instability. Screening & Prevention: Experts say cost, limited organized programs and smoking stigma are keeping eligible adults from lung cancer screening. Outbreak Watch: WHO urged vigilance in Kenya after a second Ebola case, as health authorities quarantine contacts and strengthen preparedness. Prescribing: A Cochrane review of 93 studies found pharmaceutical promotion can influence doctors’ prescribing, raising concerns about treatment choices and costs.

Cancer Advances: Retlirafusp alfa improved overall survival in a phase 3 trial for HER2-negative gastric cancer, while the FDA expanded ANKTIVA’s approval for papillary bladder cancer. AI Drug Development: AstraZeneca and insitro signed a deal worth up to $1.5 billion to discover treatments for MASH and cardiomyopathies, reflecting pharma’s growing investment in AI research. Device Safety: The FDA flagged an Edwards heart-valve delivery system after reports of a death and an injury. Drug Access: India is tightening patent rules to curb evergreening and speed access to generic medicines. Public Health: A large study linked short-term PM2.5 exposure to higher hospitalisation risk for up to three weeks, extending concerns beyond respiratory illness. Alzheimer’s Research: Many willing volunteers are screened out of trials; the World Alzheimer Report says 44% of applicants for mild Alzheimer’s trials and 88% for preclinical trials do not qualify.

Seasonal Vaccines: With CDC advisory recommendations stalled amid litigation, major medical societies issued guidance on respiratory-virus vaccines for fall. Drug Approvals: The FDA approved pritelivir for hard-to-treat herpes in immunocompromised adults; trial results showed better lesion healing and fewer adverse reactions than comparator treatments. The agency also expanded a bladder-cancer treatment option for some patients whose cancer persists after BCG therapy. R&D Deals: AstraZeneca struck an AI drug-discovery deal with insitro worth up to $1.5 billion, while Gilead and Vir agreed to a $1.9 billion collaboration on next-generation cancer therapies. Care Access: An Oregon cancer patient’s insurer twice denied coverage for a recommended drug costing more than $63,000 every three weeks, spurring community support. Industry Oversight: The FTC and seven states are asking a court to find Martin Shkreli in contempt, alleging he traded pharmaceutical stocks despite a lifetime ban from the industry. Diagnostics: Labcorp agreed to buy BioReference assets for up to $872 million.

Weight-Loss Treatment: Ireland’s HSE is considering reimbursement for Mounjaro and other GLP-1 drugs, a move that could widen access beyond the currently covered Saxenda. Diabetes Pipeline: Retatrutide delivered an average 18.8% weight loss in a Phase III trial involving people with type 2 diabetes, adding to competition in a fast-growing treatment market. Cancer Care: The FDA accepted a resubmitted application for tab-cel, a potential treatment for a rare, serious transplant-related lymphoma, while also approving a new bladder cancer treatment for some patients whose disease has not responded to BCG. Drug Discovery: AstraZeneca will pay insitro $40 million upfront to use its AI platform to find treatments for severe liver and heart conditions; the deal could reach $1.5 billion in milestones. Healthcare Access: England is unlikely to meet its elective-treatment target as waiting-list progress stalls, renewing concerns about delays in care. Biodefence: Norgen Biotek launched detection kits for Ebola and hantavirus, targeting faster pathogen surveillance for public health and research teams.

NHS Waiting Times: Progress on elective care in England has stalled, with about 65% of patients treated within 18 weeks—well short of the government’s 92% goal for 2029. September also brought record A&E attendance and waits. Medical Training: The Royal College of Physicians says training quality needs the same scrutiny as patient safety, warning that weak education risks future care and workforce capacity. Bladder Cancer: The FDA expanded approval of nogapendekin alfa inbakicept with BCG for certain patients with BCG-unresponsive bladder cancer, offering an option that may help some avoid bladder removal. Rare Diseases: The FDA’s new framework aims to tailor drug development and review for small patient populations; only about 5% of rare diseases have an approved treatment. AI Drug Design: UW researchers used AI to create protein “scissors” that target disease-linked proteins, an early approach being explored for neurodegenerative diseases and other conditions. Cancer Research Deals: Gilead and Vir struck a collaboration worth up to $1.87 billion to develop three masked T-cell engager candidates for solid tumors.

Drug-industry oversight: The FTC and seven states are asking a federal judge to hold Martin Shkreli in contempt, alleging he violated a lifetime ban by trading pharmaceutical stocks and commenting on drugmakers. Home health: ROSE has launched a $399 tap-water test that screens for more than 100 contaminants, including PFAS, and provides personalized recommendations. Cancer research: Vir Biotechnology and Gilead will develop three masked T-cell therapies for solid tumors; Vir could receive up to $1.87 billion in upfront, milestone and royalty payments. Obesity drugs: South Korea’s Hanmi plans to launch its homegrown GLP-1 treatment Eppe this month at wholesale prices below those of Wegovy and Mounjaro. Gene therapy: In a small Phase 1 trial, a single CRISPR treatment cut LDL cholesterol and triglycerides by about half at one year. Regulation and AI: The UK’s MHRA plans faster regulatory reviews and an AI tool to check clinical-trial protocols, while researchers report a way to adapt adult-trained radiology AI for children without moving patient data between hospitals.

Adolescent Cancer: Most adolescents in a colorectal cancer study were diagnosed with advanced disease: 51% had stage III cancer and 29% stage IV. Patients reported symptoms for a median of 12 weeks before diagnosis, and 45% died of the disease during the study. Pharma Oversight: The FTC and seven states are asking a judge to hold Martin Shkreli in contempt, alleging he violated his lifetime industry ban by trading drug-company stocks and commenting on their business. Rural Care: More than 40% of rural hospitals operate at a loss, an American Hospital Association report warns, putting care access at risk for millions as financial and policy pressures mount. Healthcare Costs: Employer health spending per person rose 18.8% from 2019 to 2023, with prices—not increased use—accounting for most of the rise, according to HCCI data. Obesity Drug Deal: Roche agreed to license Rona Therapeutics’ experimental RNAi obesity drug, with potential milestone payments of up to $1.06 billion.

Pharma Workforce: Drugmakers’ U.S. factory expansion faces a talent shortage: the country may need 3.8 million manufacturing workers by 2033, with about half those jobs at risk of going unfilled. Lilly is backing local training, including a $12.5 million college program in Texas. Cancer Equity: Hispanic and Latinx lung cancer patients can face risks beyond smoking and barriers to clinical trials. Experts stress biomarker testing, translated consent forms and more inclusive recruitment. Cancer Care: A Texas Oncology pilot used virtual navigation to help people manage oral cancer drugs at home, adding clinical check-ins and emotional and social support between visits. India’s Pharma Shift: Biocon’s Kiran Mazumdar-Shaw says India should build on its generics success with sustained research investment, faster approvals and a stronger pipeline of new medicines. Industry Accountability: New York’s attorney general and a bipartisan coalition want Martin Shkreli held in contempt for allegedly violating his lifetime ban from the pharmaceutical industry. AI Oversight: Hospitals are adopting AI agents for records, patient questions and scheduling faster than they can monitor them, raising cybersecurity and patient-safety concerns.

Cancer Drug Advances: RYZ101 met its Phase 3 progression-free survival endpoint in advanced gastroenteropancreatic neuroendocrine tumors, offering a potential new option after lutetium-based treatment. Surgical Robotics: Stryker is investing about $400 million in CMR Surgical and will exclusively distribute its soft-tissue surgical robot in the U.S. Imaging Strategy: Siemens Healthineers has stopped selling general ultrasound systems as it shifts toward cardiovascular and image-guided procedures. Patient Safety: Lilly is warning consumers about illegal sales of its investigational obesity drug retatrutide, which has not been approved and may pose risks from poor-quality products, dosing and inadequate monitoring. Workforce Wellbeing: A comparison of doctors in the UK and Australia finds shared pressures—including heavy workloads and training strain—pointing to workplace systems, not individual resilience alone, as a key concern.

Obesity Care: A new triple-action treatment produced 23% weight loss in people with type 2 diabetes. Lilly Israel is also launching personalized digital support for eligible patients prescribed diabetes or obesity medicines. Patient Safety: Philips recalled ultrasound systems after four reported deaths. Separately, detections of a rare, often-fatal brain fungus quadrupled at a US reference lab from 2023 to 2025, prompting calls for national surveillance. Cancer Screening: An FDA advisory panel voted 7-2 that GRAIL’s Galleri multi-cancer blood test’s benefits outweigh its risks for adults 50 and older; a final decision is expected in the coming months. Drug Supply: Experts cited overseas production dependence, manufacturer incentives and regulatory burdens as contributors to drug shortages. GSK plans to invest more than $800 million in Pennsylvania biologics production, creating over 300 jobs. Heart Failure: At-home subcutaneous furosemide reduced hospitalizations for worsening heart failure, potentially offering patients an alternative to hospital-based treatment.